Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | ALPL | P05186 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | WDR5 | P61964 | 5/20 | 0.54 |
| ▸ | EDNRB | P24530 | 2/20 | 0.54 |
| ▸ | EDNRA | P25101 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MYC | P01106 | 1/20 | 0.54 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546364 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL15880565 | 0.83 | GLA (0.68) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL27865615 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL417865 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL16012966 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL25340698 | 0.81 | L3MBTL1 (0.72) | SMN1; SMN2GLAALPLWDR5GAA | |
| SCHEMBL30519452 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL25341801 | 0.81 | NPSR1 (0.65) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL30519491 | 0.81 | NPSR1 (0.65) | SMN1; SMN2GLAALPLTSHRWDR5 | |
| SCHEMBL25342514 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2GLAALPLTSHRWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-2794600-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | Novartis AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | SMN1; SMN2 968/4885GLA 825/4885ALPL 1267/4885 |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | SMN1; SMN2 968/4885GLA 825/4885ALPL 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.